Xbrane Bioscience AB Acquires Rights to Innovative Protein Production System From Vaxiion Therapeutics, Inc.

STOCKHOLM & SAN DIEGO--(BUSINESS WIRE)--The Swedish biotech company Xbrane Bioscience and the San Diego based biotech company Vaxiion Therapeutics, Inc. have announced that they have reached a licensing arrangement granting Xbrane Bioscience rights to Vaxiion’s proprietary protein production system – the Rhamex System™. The agreement enables Xbrane Bioscience to distribute and sell the protein expression system for both research and commercial purposes in addition to utilizing the system for their in-house protein production services business.